No profile data available.
BriaCell Therapeutics Corp. (BCTX) is a healthcare company in the breast cancer treatment drugs industry, based in West Vancouver, Canada.
In Q3 2025 (the quarter ended April 30, 2025) revenue was $0. Its market capitalization was $34.02 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended July 31, 2024; market data as of October 9, 2026.
, a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
$34.02 million as of October 9, 2026.
Listed companies of a similar size in the same industry (breast cancer treatment drugs) include Puma Biotechnology, Inc. (PBYI), Greenwich LifeSciences, Inc. (GLSI), Odonate, Inc. (ODTC), Atossa Therapeutics, Inc. (ATOS).